The company, which added an additional $3M from New Sciences Ventures on top of the $3.5M led by Mesa Verde Venture Partners and other strategic partners at the end of 2016, intends to use the capital to further accelerate commercial adoption of its test. In conjuntion with the funding, New Sciences Ventures’ Dr. Grace Colón, joined the Paradigm board.
Led by David Mallery, President and CEO, provides Paradigm Diagnostics brings comprehensive and clinically actionable cancer genomic profiling to physicians and patients. The company’s sequencing based diagnostic test, PCDx, provides treating physicians and patients with precise information about the specific cancer pathways in the tumor to allow for effective decision-making.
The PCDx test analyzes DNA, RNA by NGS and Protein by IHC to provide data on the molecular alterations driving the cancer and drugs that can directly impact therapeutic decision-making.
FinSMEs
16/02/2017